3rd Annual Jefferson Urology Symposium: Men’s Health Forum

© The Canadian Journal of Urology TM : International Supplement, August 2020 23. McVary KT, Rogers T, Roehrborn CG. Rez ū m water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology 2019;126:171-179. 24. McVary K, Roehrborn C. Five year results of the prospective, randomized controlled trial of water vapor thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 2020;203(Suppl 4): e1021. 25. McVary KT, Gange SN, Gittelman MC et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. J Sex Med 2016;13(6):924-933. 26. Dixon C, Cedano ER, Pacik D et al. Efficacy and safety of Rez ū m system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2015;86(5):1042-1047. 27. Dixon CM, Cedano ER, Pacik D et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol 2016;8: 207-216. 28. ZlottaAR, Giannakopoulos X, MaehlumO, OstremT, Schulman CC. Long-termevaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003;44(1):89-93. 29. Hill B, Belville W, Bruskewitz R et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004;171(6 Pt 1):2336-2340. 30. Rosario DJ, Phillips JT, Chapple CR. Durability and cost- effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha- adrenergic antagonist therapy fails. J Urol 2007;177(3):1047-1051; discussion 1051. 31. Miller PD, Kastner C, Ramsey EW, Parsons K. Cooled thermotherapy for the treatment of benign prostatic hyperplasia: durability of results obtained with the Targis System. Urology 2003;61(6):1160-1164; discussion 1164-1165. 32. Mattiasson A, Wagrell L, Schelin S et al. Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 2007;69(1):91-96; discussion 96-97. 33. Mynderse LA, Roehrborn CG, PartinAW, Preminger GM, Coté EP. Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. J Urol 2011;185(5): 1804-1810. 34. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol 2006;50(5):969-979; discussion 980. 35.Woo HH, Chin PT, McNicholas TAet al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 2011;108(1):82-88. 36. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997;31(3):272-280. 37. Shore N, Freedman S, Gange S et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol 2014;21(1):7094-7101. 38. Barkin J, Giddens J, Incze P, Casey R, Richardson S, Gange S. Urolift system for relief of prostate obstruction under local anesthesia. Can J Urol 2012;19(2):6217-6222. 39. Chin PT, Bolton DM, Jack G et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2012;79(1):5-11. 40. Roehrborn CG, Gange SN, Shore ND et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. study. J Urol 2013;190(6):2161-2167. 41. Roehrborn CG, Barkin J, Gange SN et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017;24(3):8802-8813. 42. Gratzke C, Barber N, Speakman MJ et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 2017;119(5):767-775. 43. Sievert KD, Schonthaler M, Berges R et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol 2019; 37(7):1353-1360. 44. Roehrborn CG, Gange SN, Shore ND et al. Durability of the prostate urethral lift: 2-year results of the LIFT study. Urol Pract 2015;2(1):26-32. 45. Eure G, Gange S, Walter P et al. Real-world evidence of prostatic urethral lift confirms pivotal clinical study results: 2-year outcomes of a retrospective multicenter study. J Endourol 2019;33(7):576-584. 46. Rukstalis D, Grier D, Stroup SP et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12 month results of the MedLift study. Prostate Cancer Prostatic Dis 2019;22(3):411-419. Das ET AL. 10